How long is it possible to continue the chemotherapy for recurrent XXXX ?

@entity1 @entity43 @entity137 @entity3003 @entity1311 @entity902
UNASSIGNED: 5126 Background: Although the majority of @entity1 with advanced @entity43 will recur, there is no standard regimen for these @entity1 . We evaluated @entity137 and number of chemotherapy courses for recurrent @entity43 . METHODS: Since 1991, sixty-five @entity1 with recurrent @entity43 have received chemotherapy. Of 65 @entity1 , 16 @entity1 had more than 10 courses of same regimen of @entity1311 or @entity3003 as the second or the third or the forth line chemotherapy. Retrospective chart view was performed and clinical data obtained. @entity137 and disease status were assessed in all @entity1 . RESULTS: Median age of the @entity1 is 57 y.o.( range 35 to 69). Eleven @entity1 had @entity902 based chemotherapy without @entity1311 and 5 @entity1 received @entity902 plus @entity1311 chemothrapy as the first line therapy. Median interval from the end of the first line chemotherapy to recurrence was 12 months (range 1-108 months). Three @entity1 received single agent @entity3003 for 12, 23 and 63+ courses. Fourteen @entity1 received 10 to 52+ courses of @entity1311 (median 17). Nine @entity1 received @entity1311 and @entity3003 altanatively. The median follow-up duration was 41 months (range: 9-126). Eight @entity1 are alive with disease and continuing chemotherapy. CONCLUSIONS: Today, we do not have standard regimen for recurrent @entity43 and many new drugs are under clinical study. At time of last follow up, upto 63 courses of @entity3003 and upto 52 courses of @entity1311 therapy were possible. @entity3003 and @entity1311 is widely used as the first line chemotherapy and the @entity137 are well known. Then these drugs are familiar and easy to use for clinicians. For some group of recurrent @entity1 , those two drugs are also effective and tolerable to use for multiple courses as single agent for a long duration and contribute to prolongate these @entity1 life. No significant financial relationships to disclose.
